See more : Advanced Engine Technologies, Inc. (AENG) Income Statement Analysis – Financial Results
Complete financial analysis of Gossamer Bio, Inc. (GOSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gossamer Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- FERMENTALG (ALGAE.PA) Income Statement Analysis – Financial Results
- Natural Harmony Foods, Inc. (NHYF) Income Statement Analysis – Financial Results
- Pathfinder Minerals plc (PFP.L) Income Statement Analysis – Financial Results
- Lexston Life Sciences Corp. (LEXTF) Income Statement Analysis – Financial Results
- PT Delta Djakarta Tbk (DLTA.JK) Income Statement Analysis – Financial Results
Gossamer Bio, Inc. (GOSS)
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.39M | 4.43M | 5.17M | 4.27M | 3.09M | 297.00K | 0.00 | 0.00 |
| Gross Profit | -4.39M | -4.43M | -5.17M | -4.27M | -3.09M | -297.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 145.30M | 170.92M | 170.27M | 160.85M | 143.40M | 55.28M | 891.00K | 0.00 |
| General & Administrative | 38.46M | 47.61M | 45.78M | 49.73M | 39.14M | 44.05M | 262.00K | 83.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.46M | 47.61M | 45.78M | 49.73M | 39.14M | 44.05M | 262.00K | 83.00K |
| Other Expenses | 0.00 | 1.51M | 799.00K | -174.00K | 5.83M | 316.00K | 0.00 | 0.00 |
| Operating Expenses | 183.76M | 218.53M | 216.05M | 210.58M | 182.54M | 99.33M | 1.15M | 83.00K |
| Cost & Expenses | 183.76M | 218.53M | 216.05M | 210.58M | 182.54M | 99.33M | 1.15M | 83.00K |
| Interest Income | 2.00M | 1.58M | 761.00K | 3.44M | 3.63K | 1.72M | 0.00 | 0.00 |
| Interest Expense | 13.51M | 13.88M | 19.44M | 12.67M | 0.00 | 12.00K | 118.00K | 0.00 |
| Depreciation & Amortization | 1.61M | 4.43M | 5.17M | 4.27M | 3.09M | 297.00K | 1.15M | 83.00K |
| EBITDA | -172.15M | -211.07M | -209.32M | -233.96M | -186.14M | -148.99M | -6.65M | -83.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -183.76M | -218.59M | -216.12M | -233.96M | -186.14M | -148.99M | -6.65M | -83.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.94M | -10.79M | -17.88M | -9.40M | 5.83M | 2.02M | -118.00K | 0.00 |
| Income Before Tax | -179.82M | -229.38M | -234.00M | -243.36M | -180.31M | -146.97M | -6.77M | -83.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 10.85M | 15.07M | 8.22M | 511.00K | 2.04M | -5.38M | -83.00K |
| Net Income | -179.82M | -240.23M | -249.08M | -251.58M | -180.82M | -146.97M | -6.77M | -83.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | 0.00 |
| EPS Diluted | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | 0.00 |
| Weighted Avg Shares Out | 152.62M | 84.57M | 74.84M | 68.51M | 54.74M | 60.40M | 24.83M | 24.83M |
| Weighted Avg Shares Out (Dil) | 152.62M | 84.57M | 74.84M | 68.51M | 54.74M | 60.40M | 24.83M | 24.83M |
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q4 2020 Results - Earnings Call Transcript
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update
Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021
Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021
Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021
Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021
Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020
Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020
Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer
Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports